Table 2.
Extrapolations of central nervous system (CNS) complications from COVID-19 based on hypothetical saturation rates of the world population by the end of the pandemic according to base rate estimates using severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) data [10].
| Population | Population size (millions), na | CNS complications based on hypothetical saturation rates, n | ||
|
|
|
|
30% saturation | 70% saturation |
| Global | 7794.80 |
|
|
|
|
|
SARS (0.04%) |
|
93,537,600 | 218,254,400 |
|
|
MERS (0.20%) |
|
467,688,000 | 1,091,272,000 |
| Europe | 747.636 |
|
|
|
|
|
SARS (0.04%) |
|
8,971,632 | 20,933,808 |
|
|
MERS (0.20%) |
|
44,858,160 | 104,669,040 |
| Germany | 83.7839 |
|
|
|
|
|
SARS (0.04%) |
|
1,005,406 | 2,345,949 |
|
|
MERS (0.20%) |
|
5,027,034 | 11,729,746 |
| United States | 331.00 |
|
|
|
|
|
SARS (0.04%) |
|
39,720,000 | 92,680,000 |
|
|
MERS (0.20%) |
|
198,600,000 | 463,400,000 |
| India | 1380.00 |
|
|
|
|
|
SARS (0.04%) |
|
16,560,000 | 38,640,000 |
|
|
MERS (0.20%) |
|
82,800,000 | 193,200,000 |
| Brazil | 1380.00 |
|
|
|
|
|
SARS (0.04%) |
|
2,550,720 | 5,951,680 |
|
|
MERS (0.20%) |
|
12,753,600 | 29,758,400 |
aPopulation mid-2020 estimates from the United Nations [14].